文献速递眼底病与葡萄膜炎白内障与屈光手术

LYNX-1:0.75%去氧肾上腺素滴眼液治疗暗光视觉障碍的3期研究

LYNX-1: A Phase 3 Study of 0.75% Phentolamine Ophthalmic Solution in Subjects With Dim Light Vision Disturbances.
PubMed 文献 · Am J Ophthalmol · 2026-09-02

这项3期多中心双盲随机安慰剂对照试验评估了0.75%去氧肾上腺素滴眼液(POS)治疗暗光视觉障碍(DLD)的疗效与安全性。约145例受试者随机接受POS或安慰剂每晚双眼各一滴治疗14天。结果显示POS组在暗光低对比度最佳矫正远视力(mLCVA)和DLD严重程度方面较安慰剂组有显著改善,治疗中出现的不良事件主要为轻度和一过性。

要点

  • POS组第8天mLCVA改善比例为13%,安慰剂组为3%(P < .05)。
  • POS组第15天mLCVA改善比例为21%,安慰剂组为3%(P < .01)。
  • POS组在DLD总体严重程度及光现象(眩光、光晕、星芒)方面较安慰剂组有显著降低(P < .01)。

核心结论

  • POS可显著改善暗光视觉减退伴暗光视觉障碍受试者的暗光低对比度最佳矫正远视力,并减轻DLD总体严重程度及光现象。
  • 治疗中出现的不良事件主要为轻度和一过性。
  • 研究结果提示POS作为改善暗光视觉障碍相关症状的潜在药物值得进一步临床研究。

研究设计与样本

  • 3期、多中心、双盲、随机、安慰剂对照试验。
  • 约145例自报DLD症状、暗光瞳孔直径≥5 mm且研究眼mLCVA为30个ETDRS字母(相当于20/63 Snellen)或更差的受试者按1:1随机接受POS或安慰剂。
  • 入组受试者中最大亚组(25例)为角膜屈光手术后状态。
  • POS或安慰剂每晚双眼各一滴,自我给药,持续14天。

主要发现

  • POS组第8天mLCVA改善比例为13%,安慰剂组为3%(P < .05)。
  • POS组第15天mLCVA改善比例为21%,安慰剂组为3%(P < .01)。
  • POS组在第8天和第15天DLD总体严重程度(1-7分量表)及光现象包括眩光、光晕和星芒(0-3分量表)较安慰剂组显著降低(P < .01)。
  • 两组在结膜充血或生命体征方面无显著差异。
  • 角膜屈光手术后患者的事后分析显示第8天和第15天mLCVA显著改善,患者报告结局指标(如DLD总体严重程度)也显著改善。

临床怎么用

  • 对于暗光视觉减退伴DLD及光现象的患者,POS可能作为潜在药物选择,但需进一步临床研究验证。
  • 角膜屈光手术后出现暗光视觉障碍的患者可能从POS治疗中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE OR PURPOSE: To evaluate the efficacy and safety of 0.75% phentolamine ophthalmic solution (POS) for the treatment of dim light disturbances (DLD) in subjects with reduced mesopic low-contrast vision, including postkeratorefractive subjects. DESIGN: Phase 3, multicenter, double-masked, randomized, placebo-controlled trial. SUBJECTS, PARTICIPANTS, AND/OR CONTROLS: About 145 subjects with self-reported symptoms of DLD, mesopic pupil diameter of ≥5 mm, and 30 ETDRS letters (equivalent to 20/63 Snellen) or worse mesopic low-contrast best-corrected distance visual acuity (mLCVA) in the study eye, were randomized 1:1 to receive POS or placebo. The largest subset (25) of the enrolled subjects was status postkeratorefractive surgery. METHODS, INTERVENTION, OR TESTING: One drop of POS or placebo was self-administered in each eye once nightly for 14 days. MAIN OUTCOME MEASURES: Assessments included visual acuity testing, pupil diameter measurement, wavefront aberrometry, intraocular pressure (IOP), slit-lamp biomicroscopy, and a questionnaire assessing visual symptoms. RESULTS: POS-treated subjects demonstrated significant improvement in mLCVA at Day 8 (13% vs 3% placebo; P < .05) and Day 15 (21% vs 3% placebo; P < .01). Subjects receiving POS reported significant reduction in overall severity of DLD (on a scale of 1-7), and photic phenomena including glare, halos and starburst (on a scale of 0-3) at Day 8 and 15 (P < .01). There was no significant difference between arms in conjunctival hyperemia or vital signs. Results from posthoc analysis of postkeratorefractive surgery patients also showed significant improvement in mLCVA at Day 8 and 15 and significant improvement in patient reported outcome measures, such as overall severity of DLD. CONCLUSIONS: POS significantly improved mesopic low-contrast best-corrected distance visual acuity in subjects with reduced mesopic vision and dim light disturbances of varying etiologies, including postkeratorefractive patients. Treatment-emergent adverse events were predominantly mild and transient. These findings suggest POS may warrant further clinical investigation as a potential pharmacologic approach for patients experiencing dim light disturbances associated with reduced mesopic low-contrast visual acuity and photic symptoms.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Pepose JS, Montaquila S, Wirta D, et al. LYNX-1: A Phase 3 Study of 0.75% Phentolamine Ophthalmic Solution in Subjects With Dim Light Vision Disturbances. Am J Ophthalmol. 2026. PMID: 42686085. doi:10.1016/j.ajo.2026.08.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。